BioMerieux SA (BMXMF)
101.91
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
BioMerieux Debt to Equity Ratio: 0.0987 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0987 |
| June 30, 2023 | 0.1014 |
| December 31, 2022 | 0.107 |
| June 30, 2022 | 0.1362 |
| December 31, 2021 | 0.1093 |
| June 30, 2021 | 0.1465 |
| December 31, 2020 | 0.1455 |
| June 30, 2020 | 0.2788 |
| December 31, 2019 | 0.2688 |
| June 30, 2019 | 0.2924 |
| December 31, 2018 | 0.3392 |
| June 30, 2018 | 0.2274 |
| December 31, 2017 | 0.2453 |
| June 30, 2017 | 0.2659 |
| December 31, 2016 | 0.28 |
| Date | Value |
|---|---|
| June 30, 2016 | 0.2601 |
| December 31, 2015 | 0.248 |
| June 30, 2015 | 0.2678 |
| December 31, 2014 | 0.2674 |
| June 30, 2014 | 0.3166 |
| December 31, 2013 | 0.3197 |
| June 30, 2013 | 0.0813 |
| December 31, 2012 | 0.0988 |
| June 30, 2012 | 0.1561 |
| December 31, 2011 | 0.1628 |
| June 30, 2011 | 0.0635 |
| December 31, 2010 | 0.0485 |
| June 30, 2010 | 0.0525 |
| December 31, 2009 | 0.0612 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0987
Minimum
Dec 2023
0.2924
Maximum
Jun 2019
0.1685
Average
0.1408
Median
Debt to Equity Ratio Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | 0.3968 |
| PHAXIAM Therapeutics SA (DELISTED) | -- |
| Genfit SA | 0.9462 |
| Innate Pharma SA | 0.7525 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 5.814B |
| Total Liabilities (Quarterly) | 1.666B |
| Shareholders Equity (Quarterly) | 4.148B |
| Current Ratio | 2.028 |
| Net Debt Paydown Yield | 0.22% |